Having trouble accessing articles? Reset your cache.

TT-223: Development discontinued

Transition and partner Eli Lilly discontinued development of TT-223 after a double-blind, placebo-controlled, U.S. Phase Ib trial in about 150

Read the full 209 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE